A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT07107204
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
116
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed or Refractory Hematologic Malignancies
Leukemia
Lymphoma
Multiple Myeloma (MM)
Interventions
DRUG:
BT02
Sponsor
Biotroy Therapeutics